COMBINATION THERAPY USING A PTPN11 INHIBITOR AND AN EGFR INHIBITOR

The present disclosure provides a method of treating cancer in a subject. The method including administering to the subject: a) a therapeutically effective amount of a PTPN11 inhibitor; and b) a therapeutically effective amount of an EGFR inhibitor, wherein the PTPN11 inhibitor is represent by formu...

Full description

Saved in:
Bibliographic Details
Main Authors STICE, James, WADE, Anna, MEYERS, Brooke, SINKEVICIUS, Kerstin, SUN, Yuting, DAMBKOWSKI, Carl, LIM, Justin, WALLACE, Eli, BELTRAN, Pedro, KOHL, Nancy
Format Patent
LanguageEnglish
Published 19.06.2025
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides a method of treating cancer in a subject. The method including administering to the subject: a) a therapeutically effective amount of a PTPN11 inhibitor; and b) a therapeutically effective amount of an EGFR inhibitor, wherein the PTPN11 inhibitor is represent by formula (I): (I) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, conformational isomer, tautomer, or a combination thereof, wherein the subscripts a and b, Y1, Y2, and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R13 are as provided herein. In particular, the present disclosure provides a method of treating a solid tumor (e.g., an advanced non-small cell lung cancer) with a therapeutically effective amount of a compound of formula (10b) (i.e., 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(Ra)-(2,3-dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one) in combination with an EGFR inhibitor such as osimertinib.
Bibliography:Application Number: US202218696952